Daptomycin for the treatment of Gram-positive microorganisms in the critically-ill patient;Daptomicina para el tratamiento de las infecciones por microorganismos grampositivos en el paciente crítico

Medicina Clinica

Volumn 135, Issue SUPPL. 3, 2010, Pages 29-35

  Álvarez Lerma, Francisco ^a   Gracia Arnillas, María Pilar ^a  

^a HOSPITAL DEL MAR   (Spain)

Author keywords

Critically ill patients; Daptomycin; EUCORE; ICU

Indexed keywords

ANTIBIOTIC AGENT; DAPTOMYCIN;

ANTIBIOTIC THERAPY; BACTEREMIA; BACTERIAL ENDOCARDITIS; BACTERICIDAL ACTIVITY; COAGULASE NEGATIVE STAPHYLOCOCCUS; CREATINE KINASE BLOOD LEVEL; CRITICALLY ILL PATIENT; DATA BASE; DISEASE SEVERITY; DRUG INDICATION; EUROPE; GRAM POSITIVE BACTERIUM; GRAM POSITIVE INFECTION; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; NONHUMAN; PATIENT COMPLIANCE; REGISTER; REVIEW; SIDE EFFECT; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 79953890952     PISSN: 00257753     EISSN: 15788989     Source Type: Journal    
DOI: 10.1016/S0025-7753(10)70038-5     Document Type: Article

References (44)

1. European Antimicrobial Resistance Surveillance System. EARSS 2007. Disponible en: http://www.rivm.nl/earss/Images/EARSS%202007-FINAL-tcm61-55933. pdf
2. Soriano A, Marco F, Martínez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46:193-200. (Pubitemid 351269157)
3. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166:2138-44.
4. Frampton JE, Curran MP. Tigecycline. Drugs. 2005;65:2623-35.
5. Carpenter CF, Chambers HF. Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. Clin Infect Dis. 2004;38:994-1000.
6. Ficha técnica de daptomicina. Disponible en: http://www.emea. europa.eu/humandocs/Humans/epar/cubicin/cubicin.htm
7. Straus SK, Hancock RE. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim Biophys Acta. 2006;1758:1215-23. (Pubitemid 44436068)
8. English BK, Maryniw EM, Talati AJ, Meals EA. Diminished macrophage inflammatory response to Staphylococcus aureus exposed to daptomycin versus vancomycin or oxacillin. Antimicrob Agents Chemother. 2006;50:2225-7.
9. Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother. 2007;51:4255-60. (Pubitemid 350209874)
10. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of gram-positive bacteria isolated from European medical centres: results of the Daptomycin Surveillance Programme (2002-2004). Clin Microbiol Infect. 2006;12:844-52.
11. Nailor MD, Sobel JD. Antibiotics for gram-positive bacterial infections: vancomycin, teicoplanin, quinupristin/dalfopristin, oxazolidinones, daptomycin, dalbavancin, and telavancin. Infect Dis Clin North Am. 2009;23:965-82.
12. Rolston KV, Segreti J, Lamp KC, Friedrich LV. Cubicin Outcome Registry and Experience (CORE) methodology. Am J Med. 2007;120 10 Suppl 1:S4-5
13. Estudio Nacional de Vigilancia de Infección Nosocomial en UCI (ENVIN-UCI). Informe de los años 2006-2209. Disponible en: http://hws.vhebron.net/envin-helics/
14. Álvarez Lerma F, Olaechea Astigarraga P, Palomar Martínez M, Insausti Ordeñana J, López Pueyo MJ; Grupo de Estudio ENVIN-HELICS. [Epidemiology of the primary and vascular catheter-related bacteriemias in critical patients admitted to an Intensive Medicine Department.] Med Intensiva. 2010;34:437-45.
15. Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillinsusceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis. 2003;36:53-9.
16. Álvarez Lerma F, Palomar M, Insausti J, Olaechea P, Alcalá MA, Blanco A; Grupo de Estudio Nacional de Vigilancia de Infección Nosocomial en UCI Infección por enterococo en pacientes ingresados en UCI. Med Clin (Barc). 2003;121:281-6. (Pubitemid 37220824)
17. Cantón R, Alvarez-Lerma F. Características diferenciales de daptomicina con respecto a otros antibióticos activos frente a cocos grampositivos multirresistentes. Med Intensiva Supl. 2008;6:17-24.
18. Wale LJ, Shelton AP, Greenwood D. Scanning electronmicroscopy of Staphylococcus aureus and Enterococcus faecalis exposed to daptomycin. J Med Microbiol. 1989;30:45-9.
19. Thallinger C, Rothenburger M, Marsik C, Wuenscher S, Popovic M, Endler G, et al. Daptomycin does not exert immunomodulatory effects in an experimental endotoxin model of human whole blood. Pharmacology. 2008;81:57-62. (Pubitemid 350124537)
20. Fowler VG Jr, Boucher HW, Corey GR, Abrutyn E, Karchmer AW, Rupp ME, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355:653-65.
21. Beauchamp D, Pellerin M, Gourde P, Pettigrew M, Bergeron MG. Effects of daptomycin and vancomycin on tobramycin nephrotoxicity in rats. Antimicrob Agents Chemother. 1990;34:139-47. (Pubitemid 20019979)
22. Couture M, Simard M, Gourde P, Lessard C, Gurnani K, Lin L, et al. Daptomycin may attenuate experimental tobramycin nephrotoxicity by elestrostatic complexation to tobramycin. Antimicrob Agents Chemother. 1994;38:742-9. (Pubitemid 24114012)
23. Gurnani K, Khouri H, Couture M, Bergeron MG, Beauchamp D, Carrier D. Molecular basis of the inhibition of gentamicin nephrotoxicity by daptomycin; an infraed spectroscopic investigation. Biochim Biophys Acta. 1995;1237:86-94.
24. Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjetc. Antimicrob Agents Microbiol. 2003;47:1318-23. (Pubitemid 36368592)
25. Bell JM, Turnidge JD, Sader HS, Jones RN. Antimicrobial activity and spectrum of daptomycin: results from the surveillance program in Australia and New Zealand (2008). Pathology. 2010;42:470-3.
26. Sauermann R, Rothenburger M, Graninger W, Joukhadar C. Daptomycin: a review 4 years after first approval. Pharmacology. 2008;81:79-91. (Pubitemid 351182681)
27. Silverman JA, Oliver N, Andrew T, Li T. Resistance studies with daptomycin. Antimicrob Agents Chemother. 2001;45:1799-802. (Pubitemid 32466351)
28. Friedman L, Alder JD, Silverman JA. Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus. Antimicrob Agents Chemother. 2006;50:2137-45. (Pubitemid 43807536)
29. Munoz-Price LS, Lolans K, Quinn JP. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis. 2005;41:565-6. (Pubitemid 41099656)
30. Montero CI, Stock F, Murray PR. Mechanisms of resistance to daptomycin in Enterococcus faecium. Antimicrob Agents Chemother. 2008;52:1167-70.
31. Firsov AA, Smirnova MV, Lubenko IY, Vostrov SN, Portnoy YA, Zinner SH. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother. 2006;58:1185-92.
32. Quinn B, Hussain S, Malik M, Drlica K, Zhao X. Daptomycin inoculum effects and mutant prevention concentration with Staphylococcus aureus. J Antimicrob Chemother. 2007;60:1380-3. (Pubitemid 350168337)
33. Pultz NJ, Stiefel U, Donskey CJ. Effects of daptomycin, linezolid, and vancomycin on establishment of intestinal colonization with vancomycin-resistant enterococci and extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae in mice. Antimicrob Agents Chemother. 2005;49:3513-6. (Pubitemid 41060606)
34. Tyrrel KL, Citron DM, Warren YA, Fernandez HT, Merriam CV, Goldstein EJ. In vitro activities od daptomycin, vancomycin, and penicillin against Clostridium difficile, C. perfringens, Finegoldia magna, and Propionibacterium acnes. Antimicrob Agents Chemother. 2006;50:2728-31. (Pubitemid 44198694)
35. Arbeit RD, Maki D, Tally FP, Camparano E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38:1673-81. (Pubitemid 38781657)
36. Sakoulas G, Golan Y, Lamp KC, Friedrich LV, Russo R. Daptomycin in the treatment of bacteraemia. Am J Med. 2007;120 10 Suppl 1:S21-7.
37. Owens RC Jr, Lamp KC, Friedrich LV, Russo R. Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin. Am J Med. 2007;120 10 Suppl 1:S6-12.
38. Levine DP, Lamp KC. Daptomycin in the treatment of patients with infective endocarditis: experience from a registry. Am J Med. 2007;120 10 Suppl 1:S28-33.
39. Lamp KC, Friedrich LV, Mendez-Vigo L, Russo R. Clinical experience with daptomycin for the treatment of patients with osteomyelitis. Am J Med. 2007;120 10 Suppl 1:S13-20.
40. Forrest GN, Donovan BJ, Lamp KC, Friedrich LV. Clinical experience with daptomycin for the treatment of patients with documented gram-positive septic arthritis. Ann Pharmacother. 2008;42:213-7. (Pubitemid 351238569)
41. Edmiston CE Jr, Goheen MP, Seabrook GR, Johnson CP, Lewis BD, Brown KR, et al. Impact of selective antimicrobial agents on staphylococcal adherence to biomedical devices. Am J Surg. 2006;192;344-54. (Pubitemid 44223382)
42. LaPlante KL, Mermel LA. In vitro activity of daptomycin and vancomycin lock solutions on staphylococcal biofilms in a central venous catheter model. Nephrol Dial Transplant. 2007;22:2239-46.
43. Raad I, Hanna H, Jiang Y, Dvorak T, Reitzel R, Chaiban G, et al. Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillinresistant Staphylococcus bacteremic isolates embedded in biofilm. Antimicrob Agents Chemother. 2007;51:1656-60.
44. Boucher H, Corey G, Filler S, Parsonnet J, Campion M, Cosgrove S, et al. Appropriateness of two-week therapy for catheter-related S. aureus bacteremia. ICAAC 2006.